Avenue Biosciences, based in Finland, is making strides in protein engineering with its latest achievement: securing $5.7 million in seed extension funding. This move, co-led by Balnord and Tesi, aims to enhance their capacity for facilitating the discovery and development of protein-based therapies. The company seeks to bridge the gap between scientific discovery and practical application in the biotechnology realm.
Previously, Avenue Biosciences has focused on leveraging the symbiosis between organic biology and machine learning. This approach was primarily influenced by academic research at the University of Helsinki. Unlike traditional methodologies that rely heavily on well-established workflows, Avenue Biosciences’ technology taps into unseen opportunities in the industry. Historical attempts at protein engineering remained on a smaller scale due to limitations in technology and a lack of expansive experimental data sources.
Why are protein biologics challenging to produce?
Complex protein biologics offer advanced treatment potential when targeting specific disease pathways, yet barriers in manufacturing persist. Existing methods have struggled due to the intricacies in the cellular processes needed to synthesize these biologics. Avenue Biosciences aims to resolve production challenges by creating a platform capable of adjusting the secretory pathway at an industrial scale, a task previously hindered by technical and methodological constraints. Rosti points out that without a well-integrated platform, the burgeoning field of protein therapeutics remains constrained.
Can AI and biology coexist efficiently in biotech?
Incorporating AI into protein engineering adds an informative layer but doesn’t replace hands-on biological experiments. Rosti emphasizes the role of experimental data as crucial in training machine-learning models. She explains that designed proteins need real-world validation despite their promising computational beginnings. Avenue Biosciences exemplifies a model where AI and experimental biology guide each other, enhancing the prediction and production process for therapeutic applications.
Looking ahead, Avenue Biosciences is poised to address bottlenecks in biologics manufacturing. The company’s current customer list includes CDMOs and pharmaceutical companies, keen on exploring new avenues as traditional secretion strategies become less effective. Balnord’s Gabriele Poteliunaite and Tesi’s Miia Kaye have expressed optimism about the potential global impact of Avenue Biosciences’ innovative solutions.
The effective integration of organic biology with machine learning can cut years off the developmental timeline of protein therapies. Avenue’s methodology tests thousands of signal peptide variants in one experiment, showcasing the efficiency of modern biotech approaches. By replacing conventional trial-and-error protocols with high-throughput screening, Avenue aims to streamline manufacturing while maintaining cost-effectiveness.
Investments will prioritize scientific capability and team expansion. The company plans to recruit additional wet-lab scientists, focusing on strengthening their foundational expertise in biologics to meet rigorous commercial demands. This strategic growth will ensure Avenue’s technology remains at the forefront of innovative therapeutic developments.
Avenue Biosciences stands as a beacon for future industry advancements when efficiently combining cutting-edge science with technological resources. This reflects a broader industry trend toward rapid, scalable, and precise therapeutic development strategies. The Finnish company represents a promising aspect of the ever-evolving biotech landscape, aspiring to set a new standard in protein engineering.
